Clinical trial readout dates for Ionis Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 ION363 Amyotrophic Lateral Sclerosis · NCT04768972 | June 2026 Primary data collected |
| Phase 3 Donidalorsen Hereditary Angioedema · NCT05392114 | December 2026 Ongoing |
| Phase 3 Olezarsen Severe Hypertriglyceridemia · NCT05681351 | March 2027 Ongoing |
| Phase 1/2 ION717 Prion Disease · NCT06153966 | April 2027 Ongoing |
| Phase 3 Olezarsen Familial Chylomicronemia Syndrome · NCT05185843 | June 2027 Ongoing |
| Phase 3 obudanersen Angelman Syndrome · NCT06914609 | August 2027 Ongoing |
| Phase 2 ION775 Hypertriglyceridemia; Severe Hypertriglyceridemia · NCT07604974 | September 2027 Recruiting |
| Phase 1/2 ION440 Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome · NCT06430385 | September 2027 Recruiting |
| Phase 3 Olezarsen Familial Chylomicronemia Syndrome · NCT05130450 | February 2028 Ongoing |
| Phase 3 obudanersen Angelman Syndrome · NCT07782827 | May 2028 Recruiting |
| Phase 1/2 ION582 Angelman Syndrome · NCT05127226 | March 2029 Ongoing |
Ionis Pharmaceuticals Inc. reported $1.93B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $110M; at that rate the cash would last about 18 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-09 |
| 8-K Other Events — often topline trial data | 2026-10-23 |
| 8-K Other Events — often topline trial data | 2026-10-21 |